Combined bevacizumab, triamcinolone show short-term efficacy for AMD-related neovascularization

In the short term, combined intravitreal bevacizumab and triamcinolone may reduce foveal edema and subfoveal fluid in patients with neovascularization due to age-related macular degeneration, according to a study by a researcher in New Jersey.

Michael Colucciello, MD, evaluated the short-term anatomical results after combined treatment with intravitreal Avastin (bevacizumab, Genentech) and triamcinolone acetonide in 30 consecutive eyes of 27 patients. All patients received 1.25 mg/0.05 mL intravitreal bevacizumab, followed immediately by 2 mg/0.05 mL triamcinolone in separate syringes.

At follow-up, optical coherence tomography measurements showed that both foveal thickness and subfoveal fluid volume were statistically significantly reduced (P < .01), according to the study.

“No complications of [IOP] greater than 30 mm Hg, endophthalmitis, retinal detachment or vitreous hemorrhage developed,” Dr. Colucciello said.

The study is published in the February issue of Journal of Pharmacology and Therapeutics.